Local Paclitaxel Delivery to Prevent Restenosis in Peripheral Arterial Disease

Peripheral Arterial Disease Clinical Trial

— ResTAP  

Official title:

Local Paclitaxel Delivery to Prevent Restenosis Using the TAPAS Catheter After Endovascular Revascularization in Patients With Previous Femoropopliteal Intervention

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT03858764
• Other study ID #: APMABR 7181
• Status: Withdrawn
• Start date: August 2013
• Est. completion date: August 2013

Study information

• Verified date: February 2019
• Source: Jane Phillips Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to determine if the addition of a catheter-based local delivery of paclitaxel into the peripheral arterial vessels in patients with peripheral arterial disease (PAD) and subsequent restenosis of the femoropopliteal region would benefit from this type of investigational intervention with a known antiproliferative agent.

Description:

Peripheral arterial disease (PAD) of the lower extremities is an extremely prevalent, and often times, disabling disorder reaching roughly 8 million people in the United States, and up to 20 percent of the population over the age of 60 to 70. Atherosclerosis commonly occurs in the superficial femoral artery (SFA) and the popliteal artery limiting blood flow to the affected vessels, as well as, the distal lower extremities. PAD of this type causes claudication in up to 35% of patients which may progress to critical limb ischemia in up to 2%.

Endovascular treatment options have significantly improved over the past decade, allowing a multitude of treatment alternatives. In the US, the number of endovascular treatments now exceed bypass surgery. Procedural success rates of greater than 90 percent can be achieved by stenting, atherectomy, and percutaneous transluminal angioplasty; however, long term patency rates have been troubled by elastic recoil or neointimal hyperplasia. Two year patency rates have been documented to range from 40-50% following balloon angioplasty. Stenting in the femoropopliteal region in attempts to improve restenosis fall short with a primary patency rate of 70-80% as seen in the FAST trial. Atherectomy is promising, but has not been studied extensively.

The inability to obtain long term patency has led us to look at our success in the coronary field where drug-eluting stents (DES) are often used. Antiproliferative drugs such as paclitaxel prevent neointimal growth and have proven patency and long term success. There have been initial animal and human studies which have shown potential in preventing restenosis by using drug coated balloons and DES. Currently, there is no FDA approved drug eluting balloon for use in femoropopliteal disease, leading us to search for alternative therapies following femoropopliteal interventions.

Paclitaxel inhibits microtubule disassembly and disrupts normal cellular processes such as protein signaling, mitosis, and migration. It is highly lipogenic and poorly water soluble. Paclitaxel has been stated to prevent restenosis through several mechanisms in vitro. These mechanisms include inhibiting proliferation and migration of human smooth muscle cells. Use of the antiproliferative agent in the peripheral arena has been conducted, but no definitive results have been achieved to date. One internal animal study showed promise in the deliverability of localized paclitaxel into targeted segments of the vessel using the TAPAS device. Concentrations of 0.67 mg/mL, 1.2 mg/mL, and 2.0 mg/mL were infused locally at a duration of 2-5 minutes within the iliofemoral segment in pigs, then aspirated from the vessel using the device. No differences in drug absorption were found among the three concentrations. Drug retention remained greater than 50% in all groups at 3 and 24 hours. The average drug concentration in the vessel wall of all groups was 1.73 ± 0.85 µg/g at 3 hours, and 1.29 ± 0.47 µg/g at 24 hours after treatment. Approximately 77% of the total drug administered was aspirated, with the assumption that the remaining drug was either absorbed in the tissue, remained in the catheter, or lost systemically. On average, plasma paclitaxel levels after treatment measured 22.5 ± 21.07 ng/mL at 2 minutes, 2.7 ± 0.85 ng/mL at 3 hours, and less than 1.2 ng/mL at 24 hours. Histology showed no inflammation, injury, or other adverse effect when compared with the contrast group.

The newly available Targeted Adjustable Pharmaceutical Application System (TAPAS)—TAPAS Catheter Therapeutic System (Spectranetics, Colorado Springs, CO, USA)—has a proximal and distal occlusion balloon with an adjustable length that allows local drug delivery to a targeted arterial segment preventing systemic effects by allowing aspiration following delivery.

The ResTAP study is a prospective, open label, observational study to assess the safety and efficacy of the delivery of paclitaxel to prevent recurrent restenosis after percutaneous intervention including atherectomy with or without stenting in patients who have restenosis after a prior endovascular revascularization.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: August 2013
• Est. primary completion date: August 2013
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• 18 years of age or older

• Rutherford Stages 2-5 plus prior history of endovascular revascularization and recurrent stenosis (in stent, post angioplasty, post atherectomy) (Table 1 )

• one or more restenotic lesions within the SFA of at least 70% of the vessel diameter

• Successful percutaneous revascularization of the femoropopliteal artery (< 20% residual stenosis by visual estimate) using standard techniques per discretion of the local operator

• The femoropopliteal Reference Vessel Diameter (RVD) must be =4.0 mm and =7.0 mm

Exclusion Criteria:

• Patient is pregnant or breast feeding. (Female subjects of childbearing potential must have negative serum pregnancy test the day of the procedure.)

• Life expectancy < 12 months.

• Contraindication to aspirin, clopidogrel or other thienopyridine, heparin, low molecular weight heparin, bivalirudin or other therapies required for procedure or follow up.

• Known allergy to contrast media that cannot adequately be pre-medicated prior to study procedure.

• Known allergy to paclitaxel.

• Uncontrolled hypercoagulability or history of HIT or HITTS syndrome.

• Simultaneous enrollment in another investigational device or drug study.

• Absence of at least 1 TIMI-3 vessel run off into the foot.

• Platelet count < 100,000/mm3.

• White blood cell count < 1.5/mm3.

• Any evidence of perforation or dye extravasation during the index procedure, even if successfully treated with a covered stent.

Related Conditions & MeSH terms

• Peripheral Arterial Disease
• Peripheral Vascular Diseases
• Restenosis

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Jane Phillips Medical Center

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Primary Patency	Loss of primary patency will occur for any clinically driven Target Lesion Revascularization (TLR) as determined by Rutherford scale on claudication and a Peak Systolic Velocity Ratio (PSVR) of > 2.5 on Duplex Ultrasound (DUS), or CTA quantified stenosis = 70%	6 months
Primary	Primary Safety	Freedom from death, major amputation in the target limb, or Target Lesion Revascularization (either surgical or endovascular)	1 month
Secondary	Primary Patency	Loss of primary patency will occur for any clinically driven Target Lesion Revascularization (TLR) or a Peak Systolic Velocity Ratio (PSVR) of > 2.5 on Duplex Ultrasound (DUS), CTA quantified stenosis = 70%	1, 3, and 12 months
Secondary	Primary Assisted Patency	Patency of the target vessel regardless of secondary interventions performed to restore blood flow after restenosis.	6, 12 months
Secondary	Secondary Patency	Patency of the target vessel regardless of secondary interventions performed to restore blood flow after re-occlusion	6, 12 months
Secondary	Functional Status	Rutherford Classification	1, 3, 6, and 12 months
Secondary	Secondary Safety	adverse events associated with the use of paclitaxel, such as, but not limited to: hypotension, anaphylactic reactions, nausea, vomiting, diarrhea pancytopenia, neuropathy, alopecia which will be determined by clinical assessment and review of systems at time of exam	1, 3, 6, 12 months